Indiva Past Earnings Performance
Past criteria checks 0/6
Indiva has been growing earnings at an average annual rate of 6.8%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually. Revenues have been growing at an average rate of 42.1% per year.
Key information
6.8%
Earnings growth rate
19.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 42.1% |
| Return on equity | n/a |
| Net Margin | -11.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Indiva makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 37 | -4 | 11 | 1 |
| 31 Dec 23 | 38 | -5 | 11 | 1 |
| 30 Sep 23 | 36 | -7 | 12 | 1 |
| 30 Jun 23 | 34 | -9 | 12 | 1 |
| 31 Mar 23 | 35 | -10 | 12 | 1 |
| 31 Dec 22 | 34 | -11 | 13 | 1 |
| 30 Sep 22 | 34 | -12 | 13 | 1 |
| 30 Jun 22 | 34 | -16 | 13 | 1 |
| 31 Mar 22 | 35 | -15 | 13 | 1 |
| 31 Dec 21 | 32 | -15 | 11 | 0 |
| 30 Sep 21 | 30 | -18 | 10 | 0 |
| 30 Jun 21 | 25 | -15 | 10 | 0 |
| 31 Mar 21 | 19 | -16 | 8 | 0 |
| 31 Dec 20 | 15 | -15 | 8 | 0 |
| 30 Sep 20 | 8 | -11 | 7 | 0 |
| 30 Jun 20 | 5 | -10 | 6 | 0 |
| 31 Mar 20 | 3 | -10 | 7 | 0 |
| 31 Dec 19 | 1 | -11 | 9 | 0 |
| 30 Sep 19 | 1 | -11 | 10 | 0 |
| 30 Jun 19 | 0 | -10 | 10 | 0 |
| 31 Mar 19 | 0 | -10 | 9 | 0 |
| 31 Dec 18 | 0 | -9 | 7 | 0 |
| 30 Sep 18 | 0 | -7 | 6 | 0 |
| 30 Jun 18 | 0 | -6 | 5 | 0 |
| 31 Mar 18 | 0 | -5 | 3 | 0 |
| 31 Dec 17 | 0 | -3 | 2 | 0 |
| 30 Sep 17 | 0 | -2 | 2 | 0 |
| 30 Jun 17 | 0 | -2 | 2 | 0 |
| 31 Mar 17 | 0 | -1 | 1 | 0 |
| 31 Dec 16 | 0 | -1 | 1 | 0 |
Quality Earnings: NDVA.F is currently unprofitable.
Growing Profit Margin: NDVA.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NDVA.F is unprofitable, but has reduced losses over the past 5 years at a rate of 6.8% per year.
Accelerating Growth: Unable to compare NDVA.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NDVA.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).
Return on Equity
High ROE: NDVA.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.